Company intelligence / Profile preview

Wiseman Research Initiatives

Beverly Hills, CA, United Statespmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Other

Overview

Wiseman Research Initiatives LLC is a privately held biotech company founded in 2006 focused on translational medicine and oncology therapeutics—specifically developing cell-based vaccines such as SV BR 1 GM targeting CSF‑3R for HER2-negative breast cancer. Its lead asset reached up to Phase 3 development before being further advanced or commercialized by BriaCell Therapeutics Corp., indicating some form of technology transfer or partnership though details are limited publicly. There are no signs that it has been acquired or gone public as of mid‑2025.

Therapeutic areas: Oncology
Modalities: VaccineBiologic
Industry: Biotech

Partnerships

BriaCell Therapeutics Corp.

Beyond the preview

Go deeper on Wiseman Research Initiatives.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wiseman Research Initiatives.

Explore the full profile